Hanmi Science, the group’s holding company, has completed the development of the six raw materials which hold the key to manufacturing mRNA vaccines.
“As a holding company, we have continuously accumulated mRNA-related technologies, a major next-generation drug development platform, and sought to win contract production deals from Pfizer, Moderna and CureVac.” said a company official. “Now, we are in a stage to yield tangible results.”
